Development of Ovarian Tissue Autograft in Order to Restore Ovarian Function

NCT02846064 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2024-07-12

No results posted yet for this study

Summary

Ovarian cryopreservation is one of the available option for preserving fertility prior to potentially sterilizing treatments. In the absence of other techniques such as in vitro folliculogenesis or injection of isolated ovarian follicles, this tissue can only be re-used by autograft. In France, the first live birth after orthotopic ovarian transplantation, was obtained by Roux et al. in 2009. This clinical trial aims to collect data on the efficiency of the graft in terms of restoration of ovarian function and live births. It will also allow us to carry out the patient follow-up after ovarian tissue cryopreservation and after autograft when achieved. In cases of neoplastic malignancies, minimal residual disease detection will be performed on ovarian tissue, to avoid any risk of cancer re-seeding.

Conditions

  • Ovarian Function Insufficiency

Interventions

PROCEDURE

Autograft of cryopreserved ovarian tissue

Orthotopic transplantation

Sponsors & Collaborators

  • CHU de Reims

    collaborator OTHER
  • University Hospital, Marseille

    collaborator OTHER
  • Nantes University Hospital

    collaborator OTHER
  • University Hospital, Lille

    collaborator OTHER
  • Central Hospital, Nancy, France

    collaborator OTHER
  • University Hospital, Toulouse

    collaborator OTHER
  • University Hospital, Grenoble

    collaborator OTHER
  • University Hospital, Bordeaux

    collaborator OTHER
  • CMCO SIHCUS, Schiltingheim

    collaborator OTHER
  • University Hospital, Rouen

    collaborator OTHER
  • University Hospital, Limoges

    collaborator OTHER
  • University Hospital, Angers

    collaborator OTHER_GOV
  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER
  • Tenon Hospital, Paris

    collaborator OTHER
  • Poissy-Saint Germain Hospital

    collaborator OTHER
  • Hôpital Jean Verdier

    collaborator OTHER
  • University Hospital, Clermont-Ferrand

    collaborator OTHER
  • Hopital Antoine Beclere

    collaborator OTHER
  • Centre Hospitalier Universitaire de Besancon

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2023-12-31
Completion
2024-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846064 on ClinicalTrials.gov